The prostanoid synthesizing enzyme cyclooxygenase-2 (COX-2) is involved in the mechanisms of cerebral ischemia, an effect mediated by prostaglandin E2 through activation of EP1 receptors. Thus, inhibition of EP1 receptors is neuroprotective in models of ischemic stroke, but the molecular mechanisms of the effect have not been fully elucidated. We used oxygen glucose deprivation (OGD) in hippocampal slices as an injury model to investigate whether the neuroprotection afforded by EP1 receptor inhibition involves the PI3K/AKT survival pathway. EP1 receptor inhibition with SC51089 or SC51322 reduced the hippocampal damage produced by ODG by 28 ± 2% and 32 ± 3%, respectively ( p b 0.05). OGD induced a transient reduction of AKT activity that was partly counteracted by SC51089. LY294002 blocked the increase in phospho-AKT evoked by SC51089 and abolished the associated protective effect. The AKT activation induced by SC51089 was associated with phosphorylation of PTEN, the phosphatase that negatively regulates AKT. Furthermore, SC51089 attenuated the mitochondrial translocation of the proapoptotic protein BAD. These data indicate that EP1 receptor inhibition improves the survival of hippocampal slices by preventing the attenuation in AKT activity induced by OGD, and by reducing the mitochondrial translocation of BAD. The findings provide evidence for a link between EP1 receptors and the PI3K/AKT survival pathway and shed light on the molecular mechanisms of the prosurvival effect of EP1 receptor inhibition.
Introduction
Cyclooxygenase-2 (COX-2) is a rate limiting enzyme for the production of prostanoids (Breyer et al., 2001; Turini and DuBois, 2002) . In brain, COX-2 expression is constitutive but is upregulated rapidly by NMDA receptor activation and by injuries such as ischemic stroke (Collaco-Moraes et al., 1996; Miettinen et al., 1997; Nogawa et al., 1997) . It is well established that COX-2 activation contributes to ischemic brain injury. Thus, COX-2 gene inactivation or pharmacological inhibition attenuates the infarct and neurological dysfunction in mice subjected to focal cerebral ischemia (Nogawa et al., 1997; Iadecola et al., 2001; Sasaki et al., 2003) . The mediator of the neurotoxic effect of COX-2 in cerebral ischemia is prostaglandin E2 (PGE2), and not superoxide, which is also produced by COX-2 (Manabe et al., 2004; Kunz et al., 2007) .
PGE2 exerts its biological actions through specific G-protein coupled transmembrane receptors (Breyer et al., 2001) . Recently, we showed that EP1 receptors are the downstream effectors of COX-2-derived PGE2. Inhibition or genetic inactivation of EP1 receptors counteracts the Ca 2+ dysregulation induced by NMDA receptor overactivation and induces neuroprotection (Kawano et al., 2006) . However, the downstream molecular events linking the restoration of Ca 2+ homeostasis with neuroprotection have not been defined.
The serine/theronine kinase AKT/PKB (protein kinase B) is a key component in the survival signaling pathway transducing growth stimuli from growth factors (Manning and Cantley, 2007) . In the central nervous system, decreased AKT activity has been linked to the neuronal death induced by NMDA receptor activation, focal ischemia, or hypoxia (Luo et al., 2003; Hirai et al., 2004) . On the other hand, increased AKT activity contributes to the neuroprotection induced by hypothermia (Zhao et al., 2005) and to the protection of human cerebral endothelial cells induced by hypoxic preconditioning (Zhang et al., 2007) . The activity of AKT depends on the availability of phosphoinisitidylinositol-3,4,5-triphosphate (PIP3), which is generated by the enzyme phosphatidylinositol 3-kinase (PI3K) (Foster et al., 2003) . The levels of PIP3 are determined by the activity of a lipid phosphatase, PTEN (phosphatase and tensin homologue deleted on chromosome 10) (Maehama and Dixon, 1998), which dephosphorylates PIP3 and converts it back to PIP2. Therefore, the biological effects of AKT are determined by the balance between the activity of PI3K and PTEN, although the influence of PTEN can be more dominant (Seo et al., 2005) .
After activation, AKT phosphorylates target proteins involved in cell growth, metabolism and survival (Manning and Cantley, 2007) . For example, AKT phosphorylates the pro-apoptotic protein
